Tuesday, August 24, 2010 8:10:49 AM
Discovery Laboratories Inc
DSCO | 8/24/2010 7:45:13 AM
WARRINGTON, Pa., Aug 24, 2010 (GlobeNewswire via COMTEX News Network) --
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7850147
Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces a realignment of the Company's executive management by appointing Dr. Thomas F. Miller as Chief Operating Officer, Mr. Charles F. Katzer as Chief Technical Officer, and Mr. John G. Cooper as President and Chief Financial Officer. These positions will report directly to Mr. W. Thomas Amick, Chairman of the Board and Interim Chief Executive Officer of Discovery Labs.
Mr. Amick commented, "We are realigning the leadership and technical talents of our executive team to strengthen our Company and better position us to execute our business plans successfully. Additionally, we intend to recruit for the Chief Executive Officer role with the goal of filling this key leadership position in 2011."
Thomas F. Miller, PhD., MBA, has been appointed Chief Operating Officer and will have responsibility for product development (including preclinical and clinical operations), regulatory affairs, and corporate and commercial development for the Company. Dr. Miller's relevant biopharmaceutical experience includes product development and commercial operations with Pfizer, Novartis, BASF Pharmaceuticals, Pharmacia, and Johnson & Johnson. Dr. Miller has significant related experience in the development of new therapies for neonatal critical care and with commercial strategy development for new synthetic alternatives to animal-derived medications. Additionally, he has developed a long-standing and well established relationship base with key neonatology and pulmonology academic thought leaders, including many currently collaborating with the Company. Dr. Miller initially joined Discovery Labs in 2004 and has most recently served as Senior Vice President, Commercial and Corporate Development.
Charles F. Katzer has been appointed Chief Technical Officer and will have responsibility for manufacturing operations, aerosol device development, formulations development, quality control and assurance, and analytical services. Mr. Katzer has over 35 years of related experience in drug manufacturing and supply, device development, and quality operations within the biopharmaceutical industry including Biological Specialties, MedImmune, U.S. Bioscience, Rhone-Poulenc Rorer and Baxter, and has successfully developed and manufactured small molecule and complex biotechnology drug products. Mr. Katzer has been with Discovery Labs since 2006, most recently serving as Senior Vice President, Manufacturing Operations.
John G. Cooper has been appointed President and Chief Financial Officer and will be responsible for the strategic and organizational development of the Company while retaining overall responsibility for the Company's financial operations. Mr. Cooper has over 25 years of experience in the life sciences industry including C.R. Bard, ENI Diagnostics, DNX Corporation, and Chrysalis Corporation, and has significant experience in managing emerging growth companies, public and private equity financings, investor relations, strategic alliances, and mergers and acquisitions. Mr. Cooper most recently served as the Company's Executive Vice President and has been Chief Financial Officer since joining Discovery Labs in 2001.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Discovery Laboratories, Inc.
CONTACT: Discovery Laboratories, Inc. John G. Cooper, President and Chief Financial Officer 215-488-9490
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
Recent WINT News
- Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/30/2024 12:15:00 PM
- Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET • GlobeNewswire Inc. • 09/26/2024 08:05:00 PM
- Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 12:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 09:21:14 PM
- Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/04/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:11 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/03/2024 01:10:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/03/2024 01:09:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/03/2024 11:22:46 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/23/2024 08:15:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/21/2024 08:55:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:30:55 PM
- Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 08/20/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 09:06:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:20:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:13:06 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:11:20 PM
- Windtree Announces New Additions and Changes to Its Board of Directors • GlobeNewswire Inc. • 08/14/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 12:33:56 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/25/2024 08:07:25 PM
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM